Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Third Opioid Abuse Deterrent Product
May 19, 2014 08:15 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 19, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in...